We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 291

Amgen and Apotex do the biosimilar patent dance
  • Foley & Lardner LLP
  • USA
  • August 27 2015

Amgen has filed a complaint under the Biologics Price Competition and Innovation Act (BPCIA), asserting that a biosimilar application filed by Apotex


Sanofi seeks IPR of Cabilly patent
  • Foley & Lardner LLP
  • USA
  • July 30 2015

On July 27, 2015, Sanofi-aventis U.S. LLC and Regeneron Pharmaceuticals, Inc. filed a petition for Inter Partes Review (IPR) of the “Cabilly II”


The value of prophetic examples
  • Foley & Lardner LLP
  • USA
  • August 13 2015

In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit affirmed the district court decision that upheld the validity of the Allergan patents relating


Lumigan patents upheld by unexpected results
  • Foley & Lardner LLP
  • USA
  • August 11 2015

In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit affirmed the district court decision that upheld the validity of the Allergan patents relating


Federal Circuit says secret prior art is prior art for all purposes
  • Foley & Lardner LLP
  • USA
  • December 11 2014

In Tyco Healthcare Group LP v. Ethicon Endo-Surgery, Inc., the Federal Circuit agreed with the district court that Ethicon's prototype constituted


Biosimilars can sit out patent dance, but may have to wait out second exclusivity period
  • Foley & Lardner LLP
  • USA
  • July 24 2015

In Amgen v. Sandoz, Fed. Cir., No. 15-1499 (July 21, 2015), a divided panel of the Federal Circuit issued its first decision interpreting the


Federal Circuit expands direct divided infringement
  • Foley & Lardner LLP
  • USA
  • August 20 2015

In an en banc, per curiam decision in Akamai Technologies, Inc. v. Limelight Networks, Inc., on remand from the Supreme Court, the Federal Circuit


Contract manufacturing makes Angiomax patents invalid under on sale bar
  • Foley & Lardner LLP
  • USA
  • July 14 2015

In The Medicines Company v. Hospira, Inc., the Federal Circuit held that a transaction with a contract manufacturer gave rise to an on sale bar that


Federal Circuit finds biosimilar patent dispute resoluation procedures optional
  • Foley & Lardner LLP
  • USA
  • July 21 2015

In Amgen v. Sandoz, a divided panel of the Federal Circuit issued its first decision interpreting the Biologics Price Competition and Innovation Act


Federal Circuit finds biosimilar patent dispute resolution procedures optional
  • Foley & Lardner LLP
  • USA
  • July 21 2015

In Amgen v. Sandoz, a divided panel of the Federal Circuit issued its first decision interpreting the Biologics Price Competition and Innovation Act